Megalencephaly-capillary malformation-polymicrogyria syndrome: genes and variants
Explore variant evidence for Megalencephaly-capillary malformation-polymicrogyria syndrome across 2 analyzed proteins (PIK3CA, RIT1). Linked ClinVar records include 23 pathogenic or likely pathogenic variants, 3 variants of uncertain significance and 1 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Megalencephaly-capillary malformation-polymicrogyria syndrome
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
22 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in PIK3CA have source records linked to Megalencephaly-capillary malformation-polymicrogyria syndrome. Association strength is not clinical gene validity.
RIT1: GTP-binding protein Rit1
It transmits growth and stress signals through RAS-MAPK and related pathways and is important in cardiovascular and nervous-system development. Germline activating variants cause Noonan syndrome, often with a high frequency of hypertrophic cardiomyopathy.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RIT1 have source records linked to Megalencephaly-capillary malformation-polymicrogyria syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): AKT3 and PIK3R2.
ClinVar pathogenic and likely pathogenic variants linked to Megalencephaly-capillary malformation-polymicrogyria syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PIK3CA P449L | 449 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA P449T | 449 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA P449S | 449 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA M1043I | 1043 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic (★★) |
| PIK3CA C378R | 378 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA R38H | 38 | PI3K-ABD | Pathogenic / likely pathogenic (★★) |
| PIK3CA E545D | 545 | PIK helical | Pathogenic / likely pathogenic (★★) |
| RIT1 R122L | 122 | Pathogenic / likely pathogenic (★★) | |
| PIK3CA R93W | 93 | PI3K-ABD | Pathogenic / likely pathogenic (★★) |
| PIK3CA G364R | 364 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA E418K | 418 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA Q546K | 546 | PIK helical | Pathogenic / likely pathogenic (★★) |
| PIK3CA D939G | 939 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic (★★) |
| PIK3CA H1047L | 1047 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic (★★) |
| PIK3CA G1049S | 1049 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic (★★) |
| PIK3CA K111N | 111 | Pathogenic / likely pathogenic (★) | |
| PIK3CA R108C | 108 | Pathogenic / likely pathogenic (★) | |
| PIK3CA P539R | 539 | PIK helical | Pathogenic / likely pathogenic (★) |
| PIK3CA M1043L | 1043 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic (★) |
| PIK3CA G106C | 106 | Pathogenic / likely pathogenic (★) | |
| PIK3CA I112N | 112 | Pathogenic / likely pathogenic (★) | |
| PIK3CA N345T | 345 | C2 PI3K-type | Pathogenic / likely pathogenic (★) |
| PIK3CA D725N | 725 | Pathogenic / likely pathogenic (★) |
Which prediction tools work for Megalencephaly-capillary malformation-polymicrogyria syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 89 out of 100
- MetaSVM: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 87 out of 100
- phyloP: 85 out of 100
- PolyPhen-2: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 75 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 60 out of 100
- ESM1b (LLR): 60 out of 100
- EVE: 49 out of 100
Same protein, different disease
- PIK3CA related overgrowth syndrome also has ClinVar records linked to PIK3CA variants; they fall partly in the same places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (30 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PIK3CA variants; they fall partly in the same places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (23 pathogenic / likely pathogenic).
- Ovarian neoplasm also has ClinVar records linked to PIK3CA variants; they fall in the same places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (5 pathogenic / likely pathogenic).
- PIK3CA constitutional syndrome also has ClinVar records linked to PIK3CA variants; they fall in the same places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (4 pathogenic / likely pathogenic).
- Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes also has ClinVar records linked to PIK3CA variants; they fall in the same places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (4 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to RIT1 variants; they fall mostly in different places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (22 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to RIT1 variants; they fall mostly in different places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (9 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to RIT1 variants; they fall mostly in different places as the Megalencephaly-capillary malformation-polymicrogyria syndrome variants (5 pathogenic / likely pathogenic).
Diseases related to Megalencephaly-capillary malformation-polymicrogyria syndrome
- Noonan syndrome, also linked to PIK3CA and RIT1
- RASopathy, also linked to RIT1
- Cowden syndrome, also linked to PIK3CA
- Noonan syndrome and Noonan-related syndrome, also linked to RIT1
- Ovarian cancer, also linked to PIK3CA
- PIK3CA related overgrowth syndrome, also linked to PIK3CA
- Hereditary breast cancer, also linked to PIK3CA
- Colorectal cancer, also linked to PIK3CA
- Gastric cancer, also linked to PIK3CA
- Urinary bladder cancer, also linked to PIK3CA
- Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes, also linked to PIK3CA
- Non-small cell lung carcinoma, also linked to PIK3CA
Frequently asked questions
Which genes have records linked to Megalencephaly-capillary malformation-polymicrogyria syndrome?
This view contains 2 analyzed proteins: PIK3CA, RIT1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 23 pathogenic or likely pathogenic variants, 3 variants of uncertain significance and 1 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 45 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center